¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inflammatory hyperplasia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gingival hyperplasia
    ÀÕ¸öÁõ½Ä
  • glandular hyperplasia
    »ùÁ¾Áõ½Ä
  • hyperplasia
    °ú´ÙÇü¼º, °úÇü¼º, Áõ½Ä(Áõ)
  • intravascular papillary endothelial hyperplasia
    Ç÷°ü³»À¯µÎ¸ð¾ç³»ÇǼ¼Æ÷Áõ½Ä
  • intraductal hyperplasia
    °ü³»Áõ½Ä
  • lentiginous melanocytic hyperplasia
    Èæ»öÁ¡¸á¶ó´Ñ¼¼Æ÷Áõ½ÄÁõ
  • lipoid adrenal hyperplasia
    ÁöÁúºÎ½Å°ú´ÙÇü¼º
  • lymphoid hyperplasia
    ¸²ÇÁ±¸Áõ½Ä
  • nodular hyperplasia
    °áÀý°ú´ÙÇü¼º
  • oral focal hyperplasia
    ÀԾȱ¹¼Ò»óÇÇÁõ½Ä
  • papillary endothelial hyperplasia
    À¯µÎ¸ð¾ç³»ÇǼ¼Æ÷Áõ½Ä
  • pseudocarcinomatous hyperplasia
    °ÅÁþ¾ÏÁ¾Áõ½Ä
  • pseudoepitheliomatous hyperplasia
    °ÅÁþ»óÇÇÁ¾Áõ½Ä
  • reactive nodular hyperplasia
    ¹ÝÀÀ¼º°áÀýÁõ½Ä
  • syringolymphoid hyperplasia
    ¶¡»ù°ü¸²ÇÁ¸ð¾çÁõ½Ä, ÇѰü¸²ÇÁ¼¼Æ÷Áõ½ÄÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • glandular hyperplasia
    »ùÁ¾Áõ½Ä
  • hyperplasia
    °ú´ÙÇü¼º, Áõ½Ä(Áõ)
  • intravascular papillary endothelial hyperplasia
    Ç÷°ü³»À¯µÎ¸ð¾ç³»ÇǼ¼Æ÷Áõ½Ä
  • lentiginous melanocytic hyperplasia
    Èæ»öÁ¡¸á¶ó´Ñ¼¼Æ÷Áõ½Ä
  • lipoid adrenal hyperplasia
    ÁöÁúºÎ½Å°ú´ÙÇü¼º
  • lymphoid hyperplasia
    ¸²ÇÁ±¸Áõ½Ä
  • nodular hyperplasia
    °áÀý°ú´ÙÇü¼º
  • oral focal v hyperplasia
    ÀԾȱ¹¼Ò»óÇÇÁõ½Ä
  • papillary endothelial hyperplasia
    À¯µÎ¸ð¾ç³»ÇǼ¼Æ÷Áõ½Ä
  • pseudocarcinomatous hyperplasia
    °ÅÁþ¾ÏÁ¾Áõ½Ä
  • pseudoepitheliomatous hyperplasia
    °ÅÁþ»óÇÇÁ¾Áõ½Ä
  • reactive nodular hyperplasia
    ¹ÝÀÀ°áÀýÁõ½Ä
  • sebaceous hyperplasia
    ÇÇÁö»ùÁõ½Ä
  • syringolymphoid hyperplasia
    ¶¡»ù°ü¸²ÇÁ¸ð¾çÁõ½Ä
  • verrucous hyperplasia
    »ç¸¶±Í¸ð¾çÁõ½Ä
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • androgenic adrenal hyperplasia
    ³²¼ºÈ£¸£¸ó »ê¼º ºÎ½Å°úÇü¼º(Ñûàõ¡­ß§àõÜùãìΦû¡à÷).
  • angiolymphoid hyperplasia
    Ç÷¸²ÇÁ°üÁõ½Ä
  • angiolymphoid hyperplasia with eosinophilia
    È£»ê±¸Áõ°¡ Ç÷¸²ÇÁ°üÁõ½Ä
  • benign lymphoid hyperplasia
    ¾ç¼º¸²ÇÁ°úÇü¼º(¡­Î¦û¡à÷).
  • breast,cystic hyperplasia
    ³¶¼º Áõ½Ä (Ò¥àõñòãÖ)
  • cardiac myocyte hyperplasia
    ½É±Ù¼¼Æ÷ °úÇü¼º(ãýÐÉá¬øà Φû¡à÷)
  • cell,hyperplasia
    °úÇü¼º(Φû¡à÷), Áõ½Ä(ñòãÖ)
  • congenital adrenal hyperplasia
    ¼±Ãµ¼º ºÎ½Å°úÇü¼º(Áõ)(¡­ÜùãìΦû¡à÷ñø).
  • congenital adrenal hyperplasia
    ¼±Ãµ¼ººÎ½Å°úÇü¼º(¡­ÜùãìΦû¡à÷)
  • congenital adrenal hyperplasia
    ¼±Ãµ¼º ºÎ½ÅÁõ½ÄÁõ
  • congenital adrenocortical hyperplasia
    ¼±Ãµ¼º ºÎ½ÅÇÇÁú°úÇü¼º(Áõ)(¡­Üùãìù« òõΦû¡à÷ñø).
  • connective tissue hyperplasia
    °áÇÕÁ¶Á÷Áõ½Ä
  • cutaneous lymphoid hyperplasia
    ÇǺΠ¸²ÇÁ°èÁõ½Ä, °úÇü¼º(Φû¡à÷)
  • dilantin gingival hyperplasia
    µô¶õƾ¼º Ä¡ÀºÁõ½ÄÁõ(¡­àõöÍó»ñòãÖñø).
  • endocervical hyperplasia
    Àڱð泻¸·°úÇü¼º(í­ÏàÌòҮدΦû¡à÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
BCH basal cell hyperplasia
CAH chronic active hepatitis; chronic aggressive hepatitis; combined atrial hypertrophy; congenital adre...
CCH C-cell hyperplasia; chronic chloride hemagglutination; chronic cholestatic hepatitis
CLAH congenital lipoid adrenal hyperplasia
CLH chronic lobular hepatitis; cleft limb-heart [syndrome]; corpus luteum hormone; cutaneous lymphoid hy...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CLH Cutaneous lymphoid hyperplasia
EH Endometrial hyperplasia
FNH Focal Nodular Hyperplasia
FEH Focal epithelial hyperplasia
IH Intimal hyperplasia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • inflammatory change
    ¿°Áõ º¯È­, ¿°Áõ¼º º¯È­
  • inflammatory diarrhea
    ¿°Áõ¼º ¼³»ç
  • inflammatory disorder
    ¿°Áõ¼º Àå¾Ö
  • inflammatory erythema
    ¿°Áõ¼º È«¹Ý
  • inflammatory joint disorder
    ¿°Áõ¼º °üÀý Àå¾Ö
  • inflammatory of jaw
    ÅÎÀÇ ¿°Áõ¼º
  • inflammatory papillary hyperpalsia
    ¿°Áõ¼º À¯µÎÁõ½Ä
    ¹ÝÀÀ¼º º´¼Ò·Î¼­ °¡Ã¶¼º º¸Ã¶¹°ÀÇ Áö¼ÓÀû »ç¿ë°ú °ü·ÃÀÌ ÀÖ´Ù. ÀÇÄ¡ ÇϹæ Á¡¸·¿¡ »ý±ä Ä­µð´ÙÁõÀº °æ±¸°³°¡ ÀÌ·¯ÇÑ Áõ½Ä¼º Á¶Á÷ ¹ÝÀºÀ» ÀÏÀ¸Å°´Â ÀڱؿøÀÌ µÈ´Ù. °æ±¸°³¿¡ ¸¹Àº ¼ÒÀ¯µÎÀÇ ºñÈİ¡ ³ªÅ¸³ª´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ÀÚ°¥ ¸ð¾ç¿¡¼­ °áÀýÇü ºñÈÄ´Â ±¸°³¸é¿¡¼­´Â ±ºÁýÈ­µÇ¾î ³ªÅ¸³ª³ª Ä¡Á¶ Á¡¸·¿¡¼­´Â ´ú ¸íÈ®Çϰųª ³ªÅ¸³ªÁö ¾Ê´Â´Ù.
  • inflammatory reaction
    ¿°Áõ ¹ÝÀÀ
    ¿°Áõ ÀÎÀÚ°¡ »ýü¿¡ ÀÛ¿ëÇÏ¸é »ýÃ¼Ãø¿¡´Â ¹æ¾î±â´ÉÀÌ »ý±ä´Ù. ±× ¿°Áõ¼Ò¿¡¼­ÀÇ Ç×ü³ª È÷½ºÅ¸¹Î, ¼¼·ÎÅä´Ñ µîÀÇ È­Çй°ÁúÀ» ÇÔÀ¯ÇÑ Ç÷Àå ¼ººÐÀ̳ª Á¶Á÷¾×ÀÇ ±¹¼ÒÀû »ïÃâ, ¹éÇ÷±¸ÀÇ Ä§À±, ȸº¹À» À§ÇÑ ¼¶À¯ Áõ»ý µîÀÇ »ýÃ¼Ãø¿¡ »ý±â´Â ¹ÝÀÀ Çö»óÀ» ¸»ÇÑ´Ù. ¿°Áõ ÀÎÀÚÀÇ Á¾·ù, ¾çÀ̳ª »ýÃ¼ÃøÀÇ »óÅ¿¡ µû¶ó¼­ ¿°Áõ ¹ÝÀÀÀÌ »ý±â´Â ¾ç»óÀº ´Ù¸£´Ù.
  • inflammatory resorption
    ¿°Áõ¼º Èí¼ö
  • inflammatory tissue
    ¿°Áõ Á¶Á÷
  • non-inflammatory
    ºñ¿°Áõ¼º
  • pelvic inflammatory disease
    °ñ¹Ý¿° Áúȯ
  • primary non-inflammatory, myogenous pain disorder
    ¿ø¹ß¼ºÀÇ ºñ¿°Áõ¼º ±ÙÀ° µ¿Åë Àå¾Ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
adrenal hyperplasia, congenital A group of inherited disorders of adrenal steroidogenesis, the physical expression of which varies with the sex of the patient, the severity of the congenital enzyme defect, and the age at which the defect makes its presence felt. The most common form, the simple virilizing form, is due to a 21-hydroxylase deficiency. There is also a salt-losing form (a more complete 21-hydroxylase deficiency), a hypertensive form (11-hydroxylase deficiency), a 17-hydroxylase deficiency form, a desmolase deficiency form, and a 3-beta-hydroxysteroid deficiency form.
(12 Dec 1998)
angiofollicular mediastinal lymph node hyperplasia Solitary masses of lymphoid tissue containing concentric perivascular aggregates of lymphocytes, occurring usually in the mediastinum or hilar region of young adults; similar changes have been reported outside the mediastinum and, if associated with interfollicular sheets of plasma cells, may progress to lymphoma or plasmacytoma.
Synonym: angiofollicular mediastinal lymph node hyperplasia, Castleman's disease.
(05 Mar 2000)
angiolymphoid hyperplasia with eosinophilia Solitary or multiple benign cutaneous nodules comprised of immature and mature vascular structures intermingled with endothelial cells and a varied infiltrate of eosinophils, histiocytes, lymphocytes, and mast cells.
(12 Dec 1998)
atypical melanocytic hyperplasia Proliferation of melanocytes showing nuclear atypicality, especially as scattered single cells high in the epidermis; interpreted by some pathologists as malignant melanoma in situ.
(05 Mar 2000)
basal cell hyperplasia Increase in the number of cells in an epithelium resembling the basal cells.
(05 Mar 2000)
benign giant lymph node hyperplasia Solitary masses of lymphoid tissue containing concentric perivascular aggregates of lymphocytes, occurring usually in the mediastinum or hilar region of young adults; similar changes have been reported outside the mediastinum and, if associated with interfollicular sheets of plasma cells, may progress to lymphoma or plasmacytoma.
Synonym: angiofollicular mediastinal lymph node hyperplasia, Castleman's disease.
(05 Mar 2000)
benign prostatic hyperplasia <urology> A benign enlargement of the prostate gland begins normally after age 50 years probably secondary to the effects of male hormones. If significant enlargement occurs, it may pinch off te urethra making urination difficult or impossible.
See: urinary retention.
Origin: Gr. Plassein = to form
(06 Aug 1998)
verrucous hyperplasia A non-invasive precursor of verrucous or squamous carcinoma of the oral mucosa, occurring in the elderly, characterised by sharp or blunt upward papillary projections of squamous epithelium.
(05 Mar 2000)
giant lymph node hyperplasia Large benign, hyperplastic lymph nodes. The more common hyaline vascular subtype is characterised by small hyaline vascular follicles and interfollicular capillary proliferations. Plasma cells are often present and represent another subtype with the plasma cells containing IgM and IgA.
(12 Dec 1998)
gingival hyperplasia Non-inflammatory enlargement of the gingivae produced by factors other than local irritation. It is characteristically due to an increase in the number of cells.
(12 Dec 1998)
cementum hyperplasia A regressive change of teeth characterised by excessive development of secondary cementum on the tooth surface. It may occur on any part of the root, but the apical two-thirds are most commonly affected.
(12 Dec 1998)
congenital adrenal hyperplasia <endocrinology> A genetic disorder present at birth characterised by a deficiency of the hormones aldosterone and cortisol and an overproduction of male sex hormones (androgens). In males this may manifest as enlarged penis, small testes and early development of masculine characteristics. In females features include ambiguous genitalia, failure to menstruate, deep voice and excessive hair.
Origin: Gr. Plassein = to form
(27 Sep 1997)
congenital sebaceous hyperplasia Misnomer for nevus sebaceus.
(05 Mar 2000)
congenital virilizing adrenal hyperplasia A series of inherited inborn errors of metabolism with hyperplasia of the adrenal cortex and overproduction of virilizing hormones. Most common forms are due to partial or complete 21-hydroxylase deficiency, leading to increased ACTH production by the pituitary, stimulating adrenal growth and function. Severe form is characterised by salt-losing state.
(05 Mar 2000)
cystic hyperplasia Formation of multiple retention cysts from obstruction of ducts or glands by hyperplasia of the lining epithelium, as in fibrocystic disease of the breast and metropathia haemorrhagica.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á